With the leading pair of immuno-oncology (I-O) agents Keytruda (pembrolizumab) and Opdivo (nivolumab) seemingly scoring new approvals by the month in major markets, it would be easy to ignore the importance of the latest nod for the latter drug in Japan.
Opdivo, which is being jointly developed and commercialized in the Asian country by US pharma major Bristol-Myers Squibb (NYSE: BMY) and Japan’s Ono Pharmaceutical (TYO: 4528), has been approved by Japan’s Ministry of Health, Labor and Welfare for the treatment of unresectable advanced or recurrent gastric cancer which has progressed after chemotherapy.
"Gastric cancer took approximately 50,000 lives in Japan last year"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze